Zydus' ZyCoV-D phase III data published by the Lancet; stock ends ~2 higher

1 Apr 2022 , 04:45 PM

Zydus Lifesciences, a global discovery-driven life sciences company, today announced that The Lancet (a reputed and well-known medical journal) has peer-reviewed and published the safety and efficacy analysis data from Phase III clinical trial of its Plasmid DNA COVID-19 vaccine ZyCoV-D.

ZyCoV-D is an intradermal vaccine administered using a needle-free applicator, available in three doses. The plug-and-play technology of the vaccine makes it efficient to adapt to the rapidly mutating SARS COV-2 virus. The EClinical Medicine Journal of The Lancet has already published the results of the Phase I part of Phase I/II clinical trial.

Speaking on the development, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Ltd. said “We are delighted that the outcomes of the Phase III trial of ZyCoV-D have been peer-reviewed and published in The Lancet. This vouches for compliance with the global best practices and stringent peer review parameters of clinical trials.”

The company carried out the trial during the peak of the second wave of COVID-19 infection. The vaccine’s efficacy stood at 66.6% at a time when the Delta Variant of the SARS COV-2 virus was the prevalent strain across India.

Zydus Lifesciences ended at Rs354.30 up by Rs5.6 or 1.61% from its previous closing of Rs348.70 on the BSE.